Drug intelligence / Profile preview

VRT-044

Development stage: Preclinical
Lead developer: Venus Remedies
Modality: Peptides
Administration: Intravenous

Overview

VRT-044 is a novel formulation of the polymyxin antibiotic colistin, developed by Venus Medicine Research Centre (VMRC). It utilizes VMRC's proprietary **Renal Guard Technology**, which is designed to mitigate colistin-associated nephrotoxicity—a significant dose-limiting side effect that restricts the clinical utility of colistin as a last-resort treatment for multi-drug resistant (MDR) infections. By reducing renal damage while maintaining potent antibacterial activity, VRT-044 aims to provide a safer therapeutic option for treating severe infections caused by antimicrobial-resistant (AMR) Gram-negative bacteria. The program is currently in the preclinical stage of development.

Other names: Colistin FormulationRenal Guard Technology Colistin

Targets

Lipid A

Beyond the preview

Go deeper on VRT-044.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRT-044.

Explore the full profile